GT
GILD icon

Glenmede Trust’s Gilead Sciences GILD Stock Holding History

Glenmede Trust’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20
Closed -$2K – 1216
2020
Q4 		$2K Buy
+20
New +$1.21K ﹤0.01% 1183

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Glenmede Trust's GILD Position: Q1 2026 in Review

Glenmede Trust reduced its Gilead Sciences (GILD) stake by 11% in Q1 2026, selling an estimated $3.83M and leaving 221,975 shares worth $30.9M. The position accounts for 0.15% of the portfolio, ranked #122.

Glenmede Trust first reported a position in GILD in Q2 2013 and has held it in 50 quarters since. The position peaked at $94M in Q2 2016. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Glenmede Trust held 221,975 shares of Gilead Sciences worth $30.9M as of Q1 2026.
  • Glenmede Trust sold 27,375 Gilead Sciences shares in Q1 2026, an estimated $3.83M.
  • Gilead Sciences made up 0.15% of Glenmede Trust's portfolio in Q1 2026, its #122 holding.
  • Glenmede Trust first reported a position in Gilead Sciences in Q2 2013 and has held it in 50 quarters since.
  • Glenmede Trust's Gilead Sciences position peaked at $94M in Q2 2016.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.